Exclusive interview with Founder Sushant Kumar on the paradigm shift in microbiome science, from DNA sequencing to functional bioenergetics, and how a more nuanced investment approach is essential for advancing the therapeutic potential of the microbiome in India.

The Business Fame profiles Genefitletics founder Sushant Kumar — his personal transformation from obesity, the loss of family members to chronic disease, and how those experiences shaped the vision of making chronic illness optional.

Sushant Kumar is featured in The Business Fame’s annual list of the most impactful leaders across pharma and biotech — recognising his work building Genefitletics as a precision-diagnostics platform grounded in microbiome science.

Genefitletics is named among Silicon India’s 10 Most Promising Life Science Startups of 2021, recognised for its pioneering microbiome diagnostics work and its PROTEBA platform’s convergence of science, AI and personalised therapeutics.

Readers House Magazine features Sushant Kumar in a long-form cover story about the entrepreneurial journey and the science behind Genefitletics — available as a collector’s print edition.

A feature-length podcast interview where Sushant Kumar discusses leaving a 22-year corporate career to tackle chronic disease, the science behind Agegorithm, and the brutal reality of building deeptech in India.

NutraIngredients Asia’s investigative feature explores Genefitletics’ move into precision probiotics, the science of individualised strain selection, and how the company’s microbiome models guide therapeutic recommendations for 317 food items and 70+ supplements.

BioSpectrum India’s editorial team speaks with Sushant Kumar about PROTEBA’s bioinformatics stack, the gap between DNA-based and functional microbiome testing, and the company’s commercial roadmap including a planned ₹1 Cr seed round.

Express Healthcare covers Genefitletics’ launch of ORAONCO — India’s first at-home test that identifies, measures and detects early and pre-tumour molecular signatures of oral cancer at stage 0–1, using saliva-based microbiome sequencing and machine learning across 27 biological pathways.

The Economic Times’ health desk covers Genefitletics’ PROTEBA platform — its ability to predict and detect chronic diseases and cancer at stage 0–1 using a multiomics approach that decodes the root cause of disease at the molecular level rather than managing symptoms.

BioSpectrum India reports on the launch of ORAHYG — Asia’s first and only oral microbiome functional activity test. The test uses saliva to analyse biochemical reactions at molecular level, applying a mathematical model to determine molecular signatures predictive of chronic diseases including cardiovascular, metabolic and autoimmune conditions.

In this in-depth Economic Times Healthworld interview, Sushant Kumar explains how the current healthcare system focuses on symptom management while missing the root molecular cause of disease, and makes the case for why microbiome functional activity — not DNA composition — is the key to decoding systemic inflammation and chronic disease onset.

DrugsControl.org — India’s authoritative source for pharmaceutical regulatory news covering CDSCO, drug approvals and health diagnostics — features Genefitletics’ work in the precision diagnostics space, highlighting its at-home microbiome testing and chronic disease detection platform for the pharmaceutical and regulatory community.